Courts in Maryland and Washington, D.C., have rejected separate lawsuits by Merck and AstraZeneca against the Centers for Medicare & Medicaid Services’ drug price negotiation program.

With the FDA expected to weigh in on its kidney transplant drug imlifidase shortly before year-end, Hansa Biopharma is mulling its stock listing options in the U.S.

HHS Secretary Robert F. Kennedy Jr. has joined President Donald Trump in a renewed effort to challenge how the United States formulates its childhood vaccine recommendations. In a Request for Information, Kennedy has asked for public comment over the next 30 days on whether vaccine classifications should be adjusted.

Almost three years into his tenure as Lundbeck’s CEO, Charl van Zyl is confident the company can prove its mettle as a “neuroscience challenger” capable of “punching above its weight.”

Less than a year after the FDA turned down the resubmitted application for the company’s leukemia prospect Dasynoc, Xspray Pharma has again hit a wall at the U.S. regulator.

Roche will invest $750 million to double the size of its Genentech unit’s manufacturing facility in Hillsboro, Oregon. The new outlay will support the construction of a fill-finish plant that will produce drug delivery devices, such as prefilled syringes and auto-injectors. The funding will also bring 250 new, high-wage jobs […]